Ultrasep ESD Pharm RP18e is a silica-based HPLC column with an endcapped wide-pore (300 Å) C18 bonded phase, developed for pharmaceutical and biotechnological applications. The wide pore size ensures excellent accessibility for peptides, proteins, and other biomacromolecules, while the endcapping process minimizes residual silanol activity. This results in sharper peak shapes and improved reproducibility, especially for basic and polar analytes.
Compared to non-endcapped C18 columns, Pharm RP18e delivers superior performance in terms of peak symmetry, robustness, and reproducibility. It is particularly suited for pharmaceutical quality control, impurity profiling, and biopharmaceutical analysis.
Ultrasep ESD Pharm RP18e combines wide-pore silica with advanced endcapping – the dependable choice for pharmaceutical and biotechnological laboratories requiring robust and reproducible C18 separations.
Wide-pore silica stationary phase (300 Å) with endcapped C18 chemistry
Strong hydrophobic retention with minimized silanol interactions
Optimized for peptides, proteins, and pharmaceutical biomolecules
High reproducibility and robust column lifetime
Available particle size: 3 µm
Pharmaceutical impurity profiling and stability-indicating assays
Analysis of peptides, proteins, and therapeutic biomolecules
Biotechnological research requiring robust wide-pore C18 selectivity
Method development with improved peak symmetry for basic and polar compounds
| Particle Size |
|
|---|---|
| Pore Size | 120 Å |
| Particle Type | |
| Separation Mode | |
| USP Code | |
| Endcapping | Yes |
| pH Range | 2 - 8 |
| Phase | Material Number |
|---|---|
| Ultrasep ESD Pharm RP18e, 3 µm | ud13.p9e. |